Abraham Mathews, MD
Hematology & Oncology · Omaha, NENPI 1568556314
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,325 of the $1,710 with a category attached, or 77.5%. It is spread thinly across 32 manufacturers, the largest accounting for just 11.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $681, 8.4 times the $81 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in NE, where the typical reported total is $3,016.
Across 69 payments — averaging $24.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$197
- Pfizer$187
- Daiichi Sankyo Inc.$131
- AstraZeneca$95
- AbbVie$83
- Sanofi$76
- plus $941 from 26 others
What the payments were for
- Food & beverage$1,32577%
- Education$38523%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 4 | $197 |
| Pfizer | 6 | $187 |
| Daiichi Sankyo Inc. | 5 | $131 |
| AstraZeneca(2 entities) | 5 | $95 |
| AbbVie | 3 | $83 |
| Sanofi | 3 | $76 |
| AVEO Pharmaceuticals, Inc. | 4 | $71 |
| Histosonics, Inc. | 1 | $69 |
| Genentech USA, Inc. | 4 | $62 |
| Gilead(2 entities) | 3 | $61 |
| Regeneron Healthcare Solutions, Inc. | 2 | $59 |
| Seagen Inc. | 1 | $58 |
| Novartis | 2 | $47 |
| Bristol Myers Squibb | 2 | $44 |
| Exelixis Inc. | 2 | $35 |
| Lilly USA, LLC | 2 | $35 |
| Beone Medicines USA, Inc. | 1 | $34 |
| Genmab U.S., Inc. | 1 | $34 |
| Merck | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $30 |
| Array Biopharma Inc | 2 | $29 |
| Rigel Pharmaceuticals, Inc. | 1 | $28 |
| Stemline Therapeutics Inc. | 1 | $25 |
| Ipsen Biopharmaceuticals, Inc | 1 | $23 |
| Mirati Therapeutics, Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $23 |
| Servier Pharmaceuticals LLC | 1 | $22 |
| GSK | 1 | $18 |
| Incyte Corporation | 1 | $17 |
| Bayer | 1 | $16 |
| Epizyme, Inc. | 1 | $12 |
How this compares
$1,710 in reported general payments places this provider in the 40th percentile of 73 hematology & oncology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 29 | $588,124 |
| ImbruvicaIbrutinib | 34 | $537,603 |
| PomalystPomalidomide | 19 | $411,734 |
| Lenalidomide | 33 | $389,022 |
| IbrancePalbociclib | 11 | $166,137 |
| PegasysPeginterferon Alfa-2a | 11 | $56,926 |
| Abiraterone Acetate | 20 | $36,189 |
| EliquisApixaban | 48 | $28,334 |
| Imatinib Mesylate | 12 | $9,396 |
| Hydroxyurea | 35 | $1,175 |
| Anastrozole | 51 | $829 |
| Dexamethasone | 37 | $730 |
| Letrozole | 31 | $665 |
| Tamoxifen Citrate | 31 | $646 |
| Dextrose 5%-0.9% NaclDextrose 5 % And 0.9 % Nacl | 35 | $508 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $44 | $588,12429 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $30 | $537,60334 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $32 | $411,73419 claims |
| PfizerIbrance, Eliquis | $187 | $194,47159 claims |
| Lilly USA, LLCOlanzapine | $35 | $3715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 73 hematology & oncology providers in Nebraska.
Other hematology & oncology in Omaha
- Mojtaba AkhtariOmaha$1.8M
- Luke NordquistOmaha$202K
- Apar Kishor GantiOmaha$138K
- Julie VoseOmaha$123K
- Peter SilbersteinOmaha$99K
- Krishna GundaboluOmaha$76K
- Vijaya BhattOmaha$58K
- Samer RennoOmaha$41K
- Timothy DoriusOmaha$24K
- Stefano TarantoloOmaha$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.